Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAP-IT
2023-507860-37-00Phase 2Authorised
- Sponsor
- Institut Curie
- Start
- Apr 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga FAPI-46 in triple-negative breast cancer (TNBC), sponsored by Institut Curie. Planned start Apr 2024; status: authorised.
02
Drugs
68Ga FAPI-46
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-507860-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507860-37-00.